SCHEMBL19274483

SCHEMBL19274483

CSc1cnc(CNC(=O)OC(C)(C)C)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.46
▸ CCNE1 P24864 3/20 0.41
▸ CDK2 P24941 3/20 0.41
▸ CCNE2 O96020 2/20 0.41
▸ CCNB2 O95067 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ CCNB3 Q8WWL7 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ FFAR2 O15552 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GLS O94925 2/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ CDK5 Q00535 1/20 0.37
▸ KDM4A O75164 1/20 0.37
▸ GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17168919 0.87 PDPK1 (0.47) PDPK1CCNE1CDK2CCNE2CCNB2
SCHEMBL19274562 0.87 PDPK1 (0.43) PDPK1CCNE1CDK2CCNE2CCNB2
SCHEMBL19274584 0.85 PDPK1 (0.46) PDPK1CCNE1CDK2CCNE2CCNB2
SCHEMBL19274577 0.83 PDPK1 (0.44) PDPK1CCNE1CDK2CCNE2CCNB2
SCHEMBL19274606 0.83 PDPK1 (0.42) PDPK1CCNE1CDK2CCNE2CCNB2
SCHEMBL19274841 0.81 PDPK1 (0.43) PDPK1CCNE1CDK2CCNE2CCNB2
SCHEMBL19274418 0.81 PDPK1 (0.47) PDPK1L3MBTL1KDM4ELMNAGLS
SCHEMBL3870395 0.81 FPR3 (0.48) PDPK1L3MBTL1KDM4ELMNAGLS
SCHEMBL19274470 0.80 PDPK1 (0.44) PDPK1CCNE1CDK2CCNE2CCNB2
SCHEMBL19990403 0.80 PDPK1 (0.47) PDPK1L3MBTL1KDM4ELMNAGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 — — WO disclosed
Send feedback